{"id":"dcc-2618","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DCC-2618 selectively inhibits multiple tyrosine kinases including KIT and PDGFRA, which are frequently mutated in gastrointestinal stromal tumors (GIST). By blocking these kinases, the drug prevents aberrant signaling that drives tumor cell proliferation and survival. It is designed to overcome resistance mechanisms that develop with earlier-generation KIT inhibitors.","oneSentence":"DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:43.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease"},{"name":"Advanced systemic mastocytosis"}]},"trialDetails":[{"nctId":"NCT05957367","phase":"PHASE1, PHASE2","title":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","status":"RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2023-09-28","conditions":"GIST","enrollment":94},{"nctId":"NCT03673501","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2019-02-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":453},{"nctId":"NCT05734105","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2023-12-13","conditions":"GIST","enrollment":54},{"nctId":"NCT04282980","phase":"PHASE2","title":"A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-04-23","conditions":"Gastrointestinal Stromal Tumors","enrollment":39},{"nctId":"NCT04633122","phase":"PHASE2","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-11-25","conditions":"Gastrointestinal Stromal Tumor(GIST)","enrollment":108},{"nctId":"NCT02571036","phase":"PHASE1","title":"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2015-11","conditions":"Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers","enrollment":282},{"nctId":"NCT03353753","phase":"PHASE3","title":"Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2018-02-27","conditions":"Gastrointestinal Stromal Tumors","enrollment":129},{"nctId":"NCT05080621","phase":"PHASE1, PHASE2","title":"Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)","status":"WITHDRAWN","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-11","conditions":"Gastrointestinal Stromal Tumors","enrollment":""},{"nctId":"NCT04148092","phase":"","title":"Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST","status":"APPROVED_FOR_MARKETING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"","conditions":"GIST - Gastrointestinal Stromal Tumor","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ripretinib","Ripretinib"],"phase":"phase_3","status":"active","brandName":"DCC-2618","genericName":"DCC-2618","companyName":"Deciphera Pharmaceuticals, LLC","companyId":"deciphera-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies. Used for Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease, Advanced systemic mastocytosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}